from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A novel small-molecular agent designed to make ribosomes become less sensitive to, or possibly ignore, premature stop codons.


Sorry, no etymologies found.


  • PTC Therapeutics, a 13-year-old biotech that has received $100 million from Genzyme, is conducting a phase III trial of its compound, ataluren, in cystic fibrosis patients with a so-called nonsense mutation.

    Gene Discovery Was Only First Step

  • The UAB study showed that ataluren allowed the protein to be made in mouse cells where it was previously absent, and it helped the body's regulatory system to restore salt and water balance in the membrane.

    News for

  • Another researcher not affiliated with UAB has reported ataluren restored up to 25 percent of the missing or abnormal protein function in mice with Duchenne muscular dystrophy.

    News for

  • In Bedwell's most well-known study, ataluren restored up to 29 percent of normal protein function in mice with cystic fibrosis.

    News for

  • Finally, just to reinforce Henri's comment that we do expect to see top line data from the registration trial for ataluren in nonsense-mutation Duchenne Muscular Dystrophy in the first half. Home Page

  • Results of a pivotal phase 2b trial of ataluren in Duchenne Eliminating cancer stem cells (CSCs) within a tumor could hold the key to successful treatments for ...


  • This drug ataluren (formerly called PTC124) also holds promise in treating more than 2,400 different genetic disorders caused by nonsense mutations.

    News for

  • Genzyme is collaborating with PTC Therapeutics Inc. on ataluren, a novel oral therapy for the treatment of genetic disorders due to nonsense mutations.


  • A pivotal phase 2b trial of ataluren in Duchenne muscular dystrophy is fully enrolled and results are anticipated in the first half of next year. Featured News and Stories

  • PTC Therapeutics Initiates Phase 2 Clinical Trial of ataluren (PTC124 (R)) in Patients with Hemophilia for releases, photos, ProfNet experts, and customized feeds just for Media.



Log in or sign up to get involved in the conversation. It's quick and easy.